Skip to main content
SpringerLink
Log in

Hypnotika und Sedativa

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2019

  • 2875 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3. Aufl. American Academy of Sleep Medicine, Darien

    Google Scholar 

  • Anonym (2007): Zolpidem (Stilnox u. a.): Schlafwandeln, „Schlafessen“ und „Schlaffahren“. Arzneitelegramm 38:31–32

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2019): Stellungnahme zu Melatonin (Schlafstörungen bei Kindern und Jugendlichen mit Autismus-Spektrum-Störung und/oder Smith-Magenis-Syndrom), Nr. 750, A19-04, Version 1.0, Stand: 11.04.2019. https://www.akdae.de/Stellungnahmen/AMNOG/A-Z/Melatonin/index.html

  • Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL (2016) Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev 34:10–22

    PubMed  Google Scholar 

  • Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41–50

    PubMed  Google Scholar 

  • Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (2005) The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20:1151–1158

    PubMed  PubMed Central  Google Scholar 

  • Cimolai N (2007) Zopiclone: is it a pharmacologic agent for abuse? Can Fam Physician 53:2124–2129

    PubMed  PubMed Central  Google Scholar 

  • Crestani F, Martin JR, Möhler H, Rudolph U (2000) Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131:1251–1254

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305–322

    PubMed  Google Scholar 

  • European Medicines Agency (2007) Circadin. Europäischer öffentlicher Beurteilungsbericht (EPAR). www.emea.europa.eu/humandocs/ PDFs/EPAR/circadin/H-695- en6.pdf

    Google Scholar 

  • Farkas RH, Unger EF, Temple R (2013) Zolpidem and driving impairment – identifying persons at risk. N Engl J Med 369:689–691

    CAS  PubMed  Google Scholar 

  • Food and Drug Administration (2019) FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. FDA Drug Safety Communication. https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia

    Google Scholar 

  • Garcia-Borreguero D, Cano-Pumarega I (2017) New concepts in the management of restless legs syndrome. BMJ 2017 Feb 27(356):j104. https://doi.org/10.1136/bmj.j104

    Article  Google Scholar 

  • Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005) Sedative hypnotics in older people with insomnia : meta-analysis of risks and benefits. Br Med J 331:1169

    Google Scholar 

  • Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE (2003) Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 23:260–268

    CAS  PubMed  Google Scholar 

  • Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378

    CAS  PubMed  Google Scholar 

  • Herxheimer A (2005) Jet lag. Clin Evid 13:2178–2183

    Google Scholar 

  • Hoffmann F, Glaeske G (2014) Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept. Verbrauch zwischen 1993 und 2012. Nervenarzt 85:1402–1409

    CAS  PubMed  Google Scholar 

  • Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (2012) Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ Dec 17(345):e8343

    Google Scholar 

  • Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW (2004) Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 164:1888–1896

    PubMed  Google Scholar 

  • Jordan AS, McSharry DG, Malhotra A (2014) Adult obstructive sleep apnoea. Lancet 383:736–747

    PubMed  Google Scholar 

  • Klotz U (1995) Benzodiazepin-Hypnotika; Pharmakokinetik. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuropsychopharmaka, Bd. 2. Springer, Wien, S 135–139

    Google Scholar 

  • Kripke DF (2016) Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res 2016 May 19(5):918. https://doi.org/10.12688/f1000research.8729.1

    Article  Google Scholar 

  • Lader M (1987) Clinical pharmacology of benzodiazepines. Ann Rev Med 38:19–28

    CAS  PubMed  Google Scholar 

  • Leach MJ, Page AT (2015) Herbal medicine for insomnia: a systematic review and meta-analysis. Sleep Med Rev 24:1–12

    PubMed  Google Scholar 

  • Mattila T, Stoyanova V, Elferink A, Gispen-de Wied C, de Boer A, Wohlfarth T (2011) Insomnia medication: do published studies reflect the complete picture of efficacy and safety? Eur Neuropsychopharmacol 21:500–507

    CAS  PubMed  Google Scholar 

  • Morin CM, Benca R (2012) Chronic insomnia. Lancet 379:1129–1141

    PubMed  Google Scholar 

  • Müller-Oerlinghausen B, Kiebgis GM (2018) Berührung – Warum wir sie brauchen und wie sie uns heilt. Ullstein leben, Berlin. ISBN 978-3-96366-006-1

    Google Scholar 

  • National Institute for Health and Care Excellence (2015) Hypnotics - Key therapeutic topic. Update information January 2017. nice.org.uk/guidance/ktt6

    Google Scholar 

  • Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still nee to learn. Sleep Med Rev 6:97–111

    PubMed  Google Scholar 

  • Perlis ML, McCall WV, Krystal AD, Walsh JK (2004) Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65:1128–1137

    CAS  PubMed  Google Scholar 

  • Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2016) Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians. Ann Intern Med 165:125–133

    PubMed  Google Scholar 

  • Randall S, Roehrs TA, Roth T (2012) Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep 35:1551–1557

    PubMed  PubMed Central  Google Scholar 

  • Riemann D, Hajak G (2009a) Insomnien. I. Ätiologie, Pathophysiologie und Diagnostik. Nervenarzt 80:1060–1069

    CAS  PubMed  Google Scholar 

  • Riemann D, Hajak G (2009b) Insomnien. II. Pharmakologische und psychotherapeutische Behandlungsmöglichkeiten. Nervenarzt 80:1327–1340

    PubMed  Google Scholar 

  • Riemann D, Baum E, Cohrs S, Crönlein T, Hajak G, Hertenstein E, Klose P, Langhorst J, Mayer G, Nissen C, Pollmächer T, Rabstein S, Schlarb A, Sitter H, Weeß HG, Wetter T, Spiegelhalder K (2017) S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen, Kapitel „Insomnie bei Erwachsenen“ (AWMF-Registernummer 063-003), Update 2016. Somnologie 21:2–44

    Google Scholar 

  • Roehrs TA, Randall S, Harris E, Maan R, Roth T (2012) Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 26:1088–1095

    CAS  PubMed  Google Scholar 

  • Sack RL (2010) Clinical practice. Jet lag. N Engl J Med 362:440–447

    CAS  PubMed  Google Scholar 

  • Sarris J, Byrne GJ (2011) A systematic review of insomnia and complementary medicine. Sleep Med Rev 15:99–106

    PubMed  Google Scholar 

  • Schlack R, Hapke U, Maske U, Busch M, Cohrs S (2013) Häufigkeit und Verteilung von Schlafproblemen und Insomnie in der deutschen Erwachsenenbevölkerung. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:740–748

    CAS  PubMed  Google Scholar 

  • Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M (2008) Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 4:487–504

    PubMed  PubMed Central  Google Scholar 

  • Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X et al (2006) Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 51:27–34

    PubMed  Google Scholar 

  • Sowa NA (2016) Idiopathic hypersomnia and hypersomnolence disorder: a systematic review of the literature. Psychosomatics 57:152–164

    PubMed  Google Scholar 

  • Stiftung Warentest (2017) Medikamente im Test. 9.000 Arzneimittel geprüft und bewertet. ISBN 978-3-86851-167-3

    Google Scholar 

  • Tröbitscher N (2019) Melatonin: Rechtslage ungewiss. https://www.apotheke-adhoc.de/nachrichten/detail/apothekenpraxis/melatonin-rechtslage-ungewiss-arzneimittel-oder-lebensmittel/

    Google Scholar 

  • Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK, Ware JC (2000) Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23:1087–1096

    CAS  PubMed  Google Scholar 

  • Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M (2014) Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014 Mar 19(348):g1996. https://doi.org/10.1136/bmj.g1996

    Article  CAS  Google Scholar 

  • Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, Khawaja IS, Diem S, Koffel E, Ouellette J, Butler M, Kane RL (2016) Pharmacologic treatment of insomnia disorder: An evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 165(103):112

    Google Scholar 

  • Winkelman JW (2015) Insomnia disorder. N Engl J Med 373:1437–1444

    CAS  PubMed  Google Scholar 

  • Yeung WF, Chung KF, Yung KP, Ng TH (2015) Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 19:75–83

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Max-Delbrück-Centrum für Molekulare Medizin, Berlin-Buch, Deutschland

    Prof. Dr. med. Martin J. Lohse

  2. Berlin, Deutschland

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin J. Lohse .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Köln, Nordrhein-Westfalen, Germany

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK, Berlin, Berlin, Germany

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lohse, M.J., Müller-Oerlinghausen, B. (2019). Hypnotika und Sedativa. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2019. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59046-1_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59046-1_30

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59045-4

  • Online ISBN: 978-3-662-59046-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation